Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274043 | 0.86 | OPRK1 (0.43) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL13212571 | 0.83 | FDPS (0.41) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL1797127 | 0.82 | OPRK1 (0.45) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL1968884 | 0.79 | OPRK1 (0.40) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL9184221 | 0.78 | OPRK1 (0.39) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL13661117 | 0.77 | OPRK1 (0.42) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL13212926 | 0.77 | FDPS (0.45) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL12384311 | 0.77 | FDPS (0.45) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL29990925 | 0.74 | KMT2A (0.38) | FDPSMEN1KMT2ATRPM5OPRK1 | |
| SCHEMBL21025017 | 0.74 | FNTA (0.44) | FDPSMEN1KMT2ATRPM5OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240472-B1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-21 | — | — | EP | disclosed |
| US-7868022-B2 | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| EP-2240472-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF -SECRETASE (BACE) | Janssen Pharmaceutica NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-7786116-B2 | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7776882-B2 | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-20090227581-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-10 | — | — | US | disclosed |
| WO-2009097401-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | WO | disclosed |
| US-20080194624-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007092846-A2 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092854-A2 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194624-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | FDPS 3101/4885MEN1 992/4885KMT2A 462/4885 |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | FDPS 1615/4885MEN1 1270/4885KMT2A 684/4885 |
| US-20090227581-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | FDPS 3751/4885MEN1 1029/4885KMT2A 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.